Tech Company Financing Transactions

TRIANA Biomedicines Funding Round

Ascenta Capital, Bessemer Venture Partners and Atlas Venture participated in a $120 million Series B funding round for TRIANA Biomedicines. The financing was announced on 12/3/2025.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

400 Totten Pond Road, Suite 120
Waltham, MA 02451
USA

Phone

Undisclosed

Website

www.trianabio.com

Email Address

Not Recorded

Overview

TRIANA Biomedicines is a venture-backed biopharmaceutical company leading a transformative approach to discover and develop novel small molecules to treat disease. Our technology enables us to identify molecules that promote the interaction between a target and another protein in a way that alters the fate or function of the target protein. These innovative "molecular glues" allow us to treat disease in entirely new ways by pursuing highly disease relevant targets that have long been considered undruggable or are inadequately addressed.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Patrick Trojer

        

Chief Scientific Officer

Jean-Christophe Harmange

        

Chief Technical Officer

Jesse Chen

        

Browse more venture capital transactions:

Prev: 12/3/2025: Lemurian Labs venture capital transaction
Next: 12/3/2025: Verkada venture capital transaction

Share this article

Where The Data Comes From

We document all VC transactions involving tech companies. VC investment data records reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary